These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

427 related articles for article (PubMed ID: 31735170)

  • 1. Immunopeptidomics of colorectal cancer organoids reveals a sparse HLA class I neoantigen landscape and no increase in neoantigens with interferon or MEK-inhibitor treatment.
    Newey A; Griffiths B; Michaux J; Pak HS; Stevenson BJ; Woolston A; Semiannikova M; Spain G; Barber LJ; Matthews N; Rao S; Watkins D; Chau I; Coukos G; Racle J; Gfeller D; Starling N; Cunningham D; Bassani-Sternberg M; Gerlinger M
    J Immunother Cancer; 2019 Nov; 7(1):309. PubMed ID: 31735170
    [TBL] [Abstract][Full Text] [Related]  

  • 2. 'Hotspots' of Antigen Presentation Revealed by Human Leukocyte Antigen Ligandomics for Neoantigen Prioritization.
    Müller M; Gfeller D; Coukos G; Bassani-Sternberg M
    Front Immunol; 2017; 8():1367. PubMed ID: 29104575
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Identification of immunogenic HLA class I and II neoantigens using surrogate immunopeptidomes.
    Tokita S; Fusagawa M; Matsumoto S; Mariya T; Umemoto M; Hirohashi Y; Hata F; Saito T; Kanaseki T; Torigoe T
    Sci Adv; 2024 Sep; 10(38):eado6491. PubMed ID: 39292790
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Proteogenomic identification of an immunogenic HLA class I neoantigen in mismatch repair-deficient colorectal cancer tissue.
    Hirama T; Tokita S; Nakatsugawa M; Murata K; Nannya Y; Matsuo K; Inoko H; Hirohashi Y; Hashimoto S; Ogawa S; Takemasa I; Sato N; Hata F; Kanaseki T; Torigoe T
    JCI Insight; 2021 Jul; 6(14):. PubMed ID: 34185709
    [TBL] [Abstract][Full Text] [Related]  

  • 5. IFNγ Modulates the Immunopeptidome of Triple Negative Breast Cancer Cells by Enhancing and Diversifying Antigen Processing and Presentation.
    Goncalves G; Mullan KA; Duscharla D; Ayala R; Croft NP; Faridi P; Purcell AW
    Front Immunol; 2021; 12():645770. PubMed ID: 33968037
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Hepatobiliary Tumor Organoids Reveal HLA Class I Neoantigen Landscape and Antitumoral Activity of Neoantigen Peptide Enhanced with Immune Checkpoint Inhibitors.
    Wang W; Yuan T; Ma L; Zhu Y; Bao J; Zhao X; Zhao Y; Zong Y; Zhang Y; Yang S; Qiu X; Shen S; Wu R; Wu T; Wang H; Gao D; Wang P; Chen L
    Adv Sci (Weinh); 2022 Aug; 9(22):e2105810. PubMed ID: 35665491
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Neoantigens in Hematological Malignancies-Ultimate Targets for Immunotherapy?
    Roerden M; Nelde A; Walz JS
    Front Immunol; 2019; 10():3004. PubMed ID: 31921218
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Proteogenomic analysis identifies neoantigens and bacterial peptides as immunotherapy targets in colorectal cancer.
    Yao P; Gao M; Hu W; Wang J; Wang Y; Wang Q; Ji J
    Pharmacol Res; 2024 Jun; 204():107209. PubMed ID: 38740147
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Neoantigen-reactive T cells exhibit effective anti-tumor activity against colorectal cancer.
    Yu Y; Zhang J; Ni L; Zhu Y; Yu H; Teng Y; Lin L; Xue Z; Xue X; Shen X; Song H; Su X; Sun W; Cai Z
    Hum Vaccin Immunother; 2022 Dec; 18(1):1-11. PubMed ID: 33689574
    [TBL] [Abstract][Full Text] [Related]  

  • 10. An Integrated Genomic, Proteomic, and Immunopeptidomic Approach to Discover Treatment-Induced Neoantigens.
    Olsson N; Heberling ML; Zhang L; Jhunjhunwala S; Phung QT; Lin S; Anania VG; Lill JR; Elias JE
    Front Immunol; 2021; 12():662443. PubMed ID: 33936100
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Proteogenomic Analysis Unveils the HLA Class I-Presented Immunopeptidome in Melanoma and EGFR-Mutant Lung Adenocarcinoma.
    Qi YA; Maity TK; Cultraro CM; Misra V; Zhang X; Ade C; Gao S; Milewski D; Nguyen KD; Ebrahimabadi MH; Hanada KI; Khan J; Sahinalp C; Yang JC; Guha U
    Mol Cell Proteomics; 2021; 20():100136. PubMed ID: 34391887
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Identification of neoantigens in oesophageal adenocarcinoma.
    Nicholas B; Bailey A; McCann KJ; Wood O; Walker RC; Parker R; Ternette N; Elliott T; Underwood TJ; Johnson P; Skipp P
    Immunology; 2023 Mar; 168(3):420-431. PubMed ID: 36111495
    [TBL] [Abstract][Full Text] [Related]  

  • 13. HLA class I loss in metachronous metastases prevents continuous T cell recognition of mutated neoantigens in a human melanoma model.
    Schrörs B; Lübcke S; Lennerz V; Fatho M; Bicker A; Wölfel C; Derigs P; Hankeln T; Schadendorf D; Paschen A; Wölfel T
    Oncotarget; 2017 Apr; 8(17):28312-28327. PubMed ID: 28423700
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Mass Spectrometry Based Immunopeptidomics for the Discovery of Cancer Neoantigens.
    Bassani-Sternberg M
    Methods Mol Biol; 2018; 1719():209-221. PubMed ID: 29476514
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Circular RNA as a source of neoantigens for cancer vaccines.
    Ren Y; Manoharan T; Liu B; Cheng CZM; En Siew B; Cheong WK; Lee KY; Tan IJ; Lieske B; Tan KK; Chia G
    J Immunother Cancer; 2024 Mar; 12(3):. PubMed ID: 38508656
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [A method of screening highly common neoantigens with immunogenicity in colorectal cancer based on public somatic mutation library].
    Qin LL; Li YJ; Liang ZR; Dai L; Li WH; Chen C; Huang YL; Zhang L; Liu SM; Qiu S; Ge YP; Peng WT; Lin XX; Zhang XQ; Dong X; Li B
    Yi Chuan; 2020 Jun; 42(6):599-612. PubMed ID: 32694118
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Dominant neoantigen verification in hepatocellular carcinoma by a single-plasmid system coexpressing patient HLA and antigen.
    Chen P; Chen D; Bu D; Gao J; Qin W; Deng K; Ren L; She S; Xu W; Yang Y; Xie X; Liao W; Chen H
    J Immunother Cancer; 2023 Apr; 11(4):. PubMed ID: 37076248
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Apparent Lack of
    Kemps PG; Zondag TC; Steenwijk EC; Andriessen Q; Borst J; Vloemans S; Roelen DL; Voortman LM; Verdijk RM; van Noesel CJM; Cleven AHG; Hawkins C; Lang V; de Ru AH; Janssen GMC; Haasnoot GW; Franken KLMC; van Eijk R; Solleveld-Westerink N; van Wezel T; Egeler RM; Beishuizen A; van Laar JAM; Abla O; van den Bos C; van Veelen PA; van Halteren AGS
    Front Immunol; 2019; 10():3045. PubMed ID: 31998317
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Multifactorial Remodeling of the Cancer Immunopeptidome by IFNγ.
    Newey A; Yu L; Barber LJ; Choudhary JS; Bassani-Sternberg M; Gerlinger M
    Cancer Res Commun; 2023 Nov; 3(11):2345-2357. PubMed ID: 37991387
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Identification of Mutated Peptides in Bladder Cancer From Exomic Sequencing Data Reveals Negative Correlation Between Mutation-Specific Immunoreactivity and Inflammation.
    Wang C; Ding Y; Liu Y; Zhang Q; Xu S; Xia L; Duan H; Wang S; Ji P; Huang W; Zhao G; Cao Z; Shen H; Wang Y
    Front Immunol; 2020; 11():576603. PubMed ID: 33329543
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 22.